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Abstract
Background: Neuropathy is a dose-limiting side effect of many chemotherapeutics, including bortezomib. The
mechanisms underlying this condition are not fully elucidated even if a contribution of neuroinflammation was
suggested. Here, we investigated the role of a chemokine family, the prokineticins (PKs), in the development of
bortezomib-induced peripheral neuropathy (BIPN), and we used a PK receptor antagonist to counteract the
development and progression of the pathology.
Methods: Neuropathy was induced in male C57BL/6J mice by using a protocol capable to induce a detectable
neuropathic phenotype limiting systemic side effects. The presence of allodynia (both mechanical and thermal) and
thermal hyperalgesia was monitored over time. Mice were sacrificed at two different time points: 14 and 28 days
after the first bortezomib (BTZ) injection. At these times, PK system activation (PK2 and PK-Rs), macrophage and
glial activation markers, and cytokine production were evaluated in the main station involved in pain transmission
(sciatic nerve, DRG, and spinal cord), and the effect of a PK receptors antagonist (PC1) on the same behavioral and
biochemical parameters was assessed. Structural damage of DRG during BTZ treatment and an eventual protective
effect of PC1 were also evaluated.
Results: BTZ induces in mice a dose-related allodynia and hyperalgesia and a progressive structural damage to the
DRG. We observed a precocious increase of macrophage activation markers and unbalance of pro- and anti-
inflammatory cytokines in sciatic nerve and DRG together with an upregulation of GFAP in the spinal cord. At
higher BTZ cumulative dose PK2 and PK receptors are upregulated in the PNS and in the spinal cord. The
therapeutic treatment with the PK-R antagonist PC1 counteracts the development of allodynia and hyperalgesia,
ameliorates the structural damage in the PNS, decreases the levels of activated macrophage markers, and prevents full
neuroimmune activation in the spinal cord.
Conclusions: PK system may be a strategical pharmacological target to counteract BTZ-induced peripheral neuropathy.
Blocking PK2 activity reduces progressive BTZ toxicity in the DRG, reducing neuroinflammation and structural damage to
DRG, and it may prevent spinal cord sensitization.
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Background
Chemotherapy-induced peripheral neuropathy (CIPN)
represents a critical side effect of many chemotherapeu-
tics, including bortezomib (BTZ), a first-generation pro-
teasome inhibitor approved for the treatment of multiple
myeloma [1, 2]. Neuropathy develops in about one third
of patients undergoing BTZ, and it is characterized by
the presence of spontaneous pain and mechanical hyper-
sensitivity leading to dose reduction or treatment dis-
continuation. The molecular mechanisms underlying
BTZ-induced peripheral neuropathy (BIPN) remain
largely unclear even if the involvement of mitochondrial
changes, oxidative stress, transient potential channels ac-
tivation [3, 4], and in particular a role of neuroinflamma-
tion has been recently suggested for CIPN and
specifically for BIPN development [5–8]. Penetration of
chemotherapeutic agents into the central nervous sys-
tem is relatively poor, whereas chemotherapeutics can
cross the blood-nerve barrier, accumulating in the dorsal
root ganglia (DRG) and peripheral nerve, exerting a
toxic action and making these stations the main direct
target of drug cytotoxicity. This condition leads to
immune cell, in particular macrophages, infiltration and
activation in these areas, promoting neuropathy prog-
ression [8–10]. We previously described a role of a re-
cently discovered family of chemokines, the prokineticins
(PKs), as modulators of immune function [11, 12] and key
players in the development of experimental pathological
pain [13, 14]. The prokineticin family includes two
proteins: the mammalian prokineticin 1 (PK1 or endo-
crine gland derived vascular endothelial growth factor
(EG-VEGF)) and PK2 (or mammalian-Bv8) and two
G-protein receptors (PK-R1 and PK-R2), widely distrib-
uted in regions of the nervous system related to pain
transmission and also expressed by immune cells [15].
We demonstrated that PKs are capable to induce a
pro-inflammatory macrophage profile, stimulating chemo-
taxis and prompting the release of pro-inflammatory
cytokines [16]. Moreover, PKs can directly induce
hypersensitivity when injected in naïve mice [17–19].
Primary sensitive neurons co-express PKRs and the
transient potential receptor vanilloid 1 (TRPV1) thus
cooperating in nociceptor sensitization [15]. In addition,
the activation of PK system in the peripheral nerves, DRG,
and spinal cord correlates with the presence of neuro-
inflammation and the development of experimental
neuropathic pain induced in mice by damage to the
sciatic nerve [14, 20, 21] or by a metabolic disorder
like diabetes [13]. In these experimental models, the
treatment with antagonists of PK system was able to
contrast or prevent the neuropathic symptomatology.
On the basis of these considerations, our hypothesis
is that PK system could represent a strategical target
to counteract BIPN.
In this paper, we investigated the role of the PK system
in the development of experimental BIPN and the thera-
peutic effect of PK-R antagonism. In order to do that,
we evaluated in sciatic nerve, DRG, and spinal cord the
activation of PK system and neuroinflammation during
the pathology progression performing biochemical and
ultrastructural analysis 14 days after the first BTZ treat-
ment (half cumulative dose) and at the end of the
chemotherapeutic schedule.
Methods
Ethic statements
All the procedures performed on animals were in com-
pliance with the international policies (EEC council
directive 86/609, OJ L 358, 1 Dec. 12, 1987; Guide for
the Care and Use of Laboratory Animals, US National
Research Council, 8th ed., 2011) and were approved by
the Animal Care and Use Committee of the Italian Min-
istry of Health (permission number 709/ 2016 to SF). All
efforts were made to reduce the number of animals used
and to minimize animal suffering in accordance with the
3R principles.
Animals
A total of 126 9-week-old C57BL/6J male mice (Charles
River, Calco, Italy) were used in this study. Mice were
housed with light/dark cycles of 12 h, temperature of 22
± 2 °C, humidity of 55 ± 10%, and food and water ad
libitum. Animals were assigned to cages (3 animals/cage)
with the help of randomly generated numbers.
BIPN induction and therapeutic treatment with the PK-Rs
antagonist PC1
Bortezomib (BTZ) (LC Laboratories; Woburn, MA) was
freshly prepared before each administration. BTZ was
dissolved in dimethylsulfoxide (DMSO) with a con-
centration of 1 mg/ml and diluted in sterile 0.9% NaCl
(saline) solution to a final concentration of 40 μg/ml
[22], and it was intraperitoneally (i.p.) injected at the
final dose of 0.4 mg/kg. For each cycle, BTZ (0.4 mg/kg)
or vehicle were administered three times a week (every
Monday, Wednesday, Friday) for a total of four con-
secutive weeks.
After verifying in mice the presence of mechanical and
thermal hypersensitivity, the PKRs antagonist PC1 [23]
was subcutaneously administered, in a therapeutic way,
at the dose of 150 μg/kg [13], two times/day for 14 days,
from day 14 until the end of the BTZ protocol (day 28).
PC1 is a triazine-guanidine derivative that in vitro blocks
PK2-induced intracellular Ca++ increase in PK-R1- and
PK-R2-transfected CHO cells and in vivo antagonizes
hyperalgesia induced by PK2. Affinity studies for PKRs
receptors indicated a Ki of 22 nM and of 1610 nM for
PK-R1 and PK-R2 respectively [23]. The chosen dose
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represents the most effective one contrasting pain as re-
sulted from previously conducted dose-finding study
performed in CCI neuropathic mice [14]. This dose was
also effective in other neuropathic pain models like
spared nerve injury model (SNI) [20] and in streptozoto-
cin model of diabetic neuropathy [13].
Experimental protocol: mechanical and heat thresholds
determination
All the behavioral evaluations were performed by re-
searchers who were blind to treatments. Behavioral eval-
uations were performed on both hind paws before
starting BTZ protocol (0), 7, 14, 21 (corresponding to 7
days of chronic PC1 treatment), and 28 (corresponding
to 14 days of chronic PC1 treatment) days after the first
BTZ administration [13]. All measurements were done
at least 14 h after the previous PC1 administration and
before its first daily injection. The antiallodynic effect of
a single PC1 injection was tested at the end of BTZ
treatment (day 28), when hypersensitivity was maximal.
Paw withdrawal thresholds were measured 30, 60, 120,
180, 210, and 240 min after PC1 injection.
Double BTZ cycle
After a classical single BTZ cycle of 28 days, mice were
monitored over time for the presence of allodynia, until
they recovered to control values. At day 84, mice started
a second BTZ cycle (using the before mentioned proto-
col) and their paw withdrawal thresholds were measured
at the same time points as before, corresponding to 91,
98, 105, and 112 from the first BTZ administration.
Mechanical allodynia
Mechanical allodynia was assessed using Dynamic Plantar
Aesthesiometer [13] (Ugo Basile, Comerio, Italy). Animals
were placed in a test cage with a wire mesh floor, and the
rigid tip of a Von Frey filament (punctate stimulus) was
applied to the skin of the mid-plantar surface of the hind
paw with increasing force (ranging up to 10 g in 10 s),
starting below the threshold of detection and increasing
until the animal removed its paw. The withdrawal thresh-
old was expressed in grams.
Cold allodynia
Cold allodynia was evaluated as previously described
[24]. Briefly, a drop (50 μl) of acetone was placed in the
middle of the plantar surface of the hind paw. Mouse
behavior was initially monitored for 20 s. If mice did not
withdraw, flick, or stamp the hind paw within this time
lapse, no other observations were made and the re-
searcher assigned the score 0 to mice. However, if within
this period the animal responded to the cooling effect of
acetone, its behavior was assessed for an additional 20 s.
Responses to acetone were graded, using a 4-point scale,
as follows: 0, no response; 1, quick withdrawal, flick, or
stamp of the paw; 2, prolonged withdrawal or repeated
flicking (more than twice) of the paw; and 3, repeated
flicking of the paw with licking directed at the plantar
surface of the hind paw. Acetone was applied three
times to each hind paw, and the responses were scored.
Mean scores were then generated for each mouse.
Thermal hyperalgesia
Thermal hyperalgesia was tested according to the Har-
greaves procedure [25], slightly modified by us for
mouse [14], using a Plantar test apparatus (Ugo Basile,
Comerio, Italy). Briefly, mice were placed in small clear
plexiglass cubicles and allowed to acclimatize. A con-
stant intensity radiant heat source (beam diameter 0.5
cm and intensity 20 I.R.) was aimed at the mid-plantar
area of the hind paw. Paw withdrawal latency (PWL),
that is the time, in seconds (s), from initial heat source
activation until paw withdrawal, was recorded.
Biochemical, immunofluorescence, and electron
microscopy evaluations
To evaluate the role of PK system and neuroinflammation
in the development and progression of BTZ-induced per-
ipheral neuropathy, mice were sacrificed at two different
time points: 14 days after the first BTZ treatment (BTZ
c.d. 2.4 mg/kg), before starting PC1 treatment; 28 days
after the first BTZ treatment (BTZ c.d. 4.8 mg/kg), time
point which corresponds to 14 days of PC1 chronic treat-
ment. Mice were killed by CO2 inhalation for blood, lum-
bar spinal cord, DRG, and sciatic nerves collection.
Nervous tissues were immediately frozen in liquid nitro-
gen and stored at − 80 °C until processing for mRNA
extraction. Blood samples were centrifuged and serum
was kept at − 20 °C until use.
All the evaluations and the subsequent statistical ana-
lysis were performed in a blind fashion.
RNA extraction and real-time qPCR
Total RNA was isolated from sciatic nerves, DRG, and
the lumbar spinal cords using TRIzol® Reagent (Invitro-
gen, ThermoFisher Scientific, Italy) according to the
manufacturer’s instructions and re-suspended in 10–20 μl
of RNase-free water. All procedures were performed as
previously described in detail [13, 26]. Specific TaqMan
probes/primers for mouse prokineticin receptors (Prokr1
Mm00517546_m1; Prokr2 Mm00769571_m1), cytokines
(IL-1β Mm00434228_m1; IL-6 Mm00446190_m1;
TNF-α Mm00443258_m1; IL-10 Mm00439616_m1),
CD68 (Mm_03047343), TLR4 (Mm00445274_m1),
and glyceraldehydes-3-phosphate dehydrogenase (GAPDH
Mm99999915_g1) were purchased from Applied Biosys-
tems. Threshold cycle numbers (Ct) of the specific gene
of interest and the endogenous control gene GAPDH
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were determined by ABI PRISM 7000 Sequence De-
tection System.
The Ct value of the specific gene of interest was normal-
ized to the Ct value of the endogenous control, GAPDH,
and the comparative Ct method (2−ΔΔCt) was then
applied using the control group (vehicle treated
mice) as calibrator.
Immunofluorescence
L4-L5 spinal cord, DRG, and sciatic nerve were dissected
from transcardially perfused mice (PBS followed by 4%
paraformaldehyde (PFA)), post-fixed in 4% PFA for 24 h,
cryoprotected in 30% sucrose solution, embedded in
cryostat medium, and frozen and cut using a cryostat.
Prior to immunofluorescence staining, all sections were
blocked with 3% normal donkey serum, containing 0.1%
Triton X-100 for 30 min at room temperature. Spinal
cord transverse sections (40 μm, free-floating) were in-
cubated at 4 °C for 48 h, whereas DRG and sciatic nerve
sections (20 μm, mounted on slides) were incubated at 4 °
C overnight with the following primary antibodies diluted
in PBS-0.3% Triton X-100: anti-PK2 (rabbit, 1:200,
AbCam, Cambridge, UK), anti-PK-R1 and anti-PK-R2
(rabbit, 1:200, Alomone labs, Jerusalem, Israel), anti-GFAP
(mouse, 1:400, Immunological Sciences, Italy), and anti-
CD68 (mouse, 1:400, AbCam, Cambridge, UK) [14]. After
washing, sections were incubated for 2 h at room
temperature with anti-species IgG secondary antibodies
coupled to Alexa Fluor®-488 or 555 (1:200, Immunological
Sciences). Nuclei were stained with DAPI (1:500, Sigma
Aldrich). Possible non-specific labeling of secondary
antibodies was detected using secondary antibody
alone. Images of stained sections were acquired using a
laser-scanning confocal microscope (Leica SP5, Leica
Microsystems, Wetzlar, Germany) connected to a digital
camera diagnostic instrument operated by I.A.S. software
of Delta Systems Italia (Milan, Italy) [14].
Quantitative image analysis
To quantify the immunofluorescence positive area of
CD68, PK2, and GFAP in the sciatic nerve and DRG,
high-magnification images were captured with a × 40
objective at zoom factor 1 using a constant set of acqui-
sition parameters. Six sections were captured from each
of five animals per group. The analysis was performed
using ImageJ software (version 1.47, http://imagej.nih.
gov/ij/index.html, free software) within three boxes of
104 μm2 per section, and a mean value was obtained by
combining values from all three boxes.
To quantify the immunofluorescence positive area of
CD68, PK2, and GFAP in the spinal cord, six L4-L6
immunofluorescence high-magnification images of the
dorsal horns were captured as described above, from each
of five animals per group. Quantification was performed
within three boxes of 104 μm2 per section that were placed
in the lateral, central, and medial areas of the dorsal horns,
and a mean value was obtained by combining values from
the three boxes.
Ultrastructural evaluations of DRG (electron microscope)
Mice were anesthetized (ketamine/xylazine i.p.) and
transcardially perfused with a fixative solution (2% para-
formaldehyde, 2% glutaraldehyde in cacodylate buffer,
pH 7.3). From each animal, DRG (L4 and L5) were
removed and immersed in the same fixative overnight at
4 °C. Subsequently, samples were washed in 0.2M caco-
dylate buffer, postfixed in 2% OsO4 (Sigma-Aldrich) in
the same buffer, washed in distilled water, and stained
with 2% aqueous uranyl acetate. Then, it was carried out
the dehydration in ethyl alcohol and embedded in
Epon-Araldite resin.
Semithin sections (0.5 μm thick) of each DRG were
stained with 0.5% toluidine blue in 1% sodium borate
and examined with a light microscope (Zeiss Axiophot)
for preliminary observations. Ultrathin sections (50 to
70 nm thick), cut on a Leica Supernova ultramicrotome,
were stained with lead citrate and examined under a
Zeiss EM10 electron microscope (Gottingen, Germany).
ELISA
Serum was obtained by centrifuging blood samples 14
and 28 days after the first BTZ treatment. Prokineticin 2
levels were measured in mice serum by means of
CSB-EL018747MO ELISA kit (Cusabio). Each sample
was tested in double. Kit sensitivity: minimum detectable
dose of mouse prokineticin 2 is 3.12 pg/ml.
Statistical analysis
Experiments were designed to minimize the number of
animals based on the results obtained in our previous
studies [13, 21] and on pre-study power analysis consid-
ering the antiallodynic response as primary endpoint.
Data are expressed as mean ± SD (six animals/group for
behavioral and biochemical evaluations)
Statistical analysis was performed as described below:
Data from behavioral analysis were analyzed by mean
of two-way ANOVA analysis of variance followed by
Bonferroni’s test for between-group comparisons in the
post hoc analysis.
For biochemical evaluations, statistical analysis was
performed at day 14 by using t test and at day 28 by
mean of one-way ANOVA followed by Bonferroni’s test
for multiple comparisons. Differences were considered
significant at p < 0.05. All the statistical analyses were
performed using GraphPad 6 software (San Diego, CA).
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Results
The dose of BTZ was chosen from the literature [22] in
order to minimize unspecific systemic toxicity. BTZ
treatment was well tolerated by animals; no mice died or
were in sufferance, maintaining explorative, grooming,
and feeding activities comparable to those of control
mice. BTZ did not induce a significant loss of weight in
the animals (data not shown).
BIPN development and effect of the PK antagonism
As shown in Fig. 1, BTZ induces in mice a
dose-related mechanical and thermal hypersensitiv-
ity characterized by the presence of allodynia
(panels a and b) and hyperalgesia (panel c). Four-
teen days after the first BTZ administration (BTZ
cumulative dose, c.d., 2.4 mg/kg), mechanical and
thermal thresholds of BTZ mice were already low-
ered if compared to those of the control mice (ve-
hicle treated; *** p < 0.001 vs CTR), and a further
decrease was evident at the end of the BTZ protocol at
day 28 (BTZ c.d. 4.8 mg/kg; +++ p < 0.001 vs BTZ day 14).
Treatment with the PK-Rs antagonist PC1 was started at
day 14, in the presence of a well-established allodynia and
hyperalgesia. PC1 was injected two times/day from day 14
until day 28, simultaneously to the BTZ treatment. After
7 days of chronic treatment (day 21), the antagonist can
efficiently counteract both mechanical (panel a) and ther-
mal allodynia (panel b) as well as thermal hyperalgesia
(panel c), and its effect is maintained for the entire
duration of treatment (°°°p < 0.001 vs BTZ).
We also evaluated the acute effect of a single
PC1 injection on mechanical allodynia at the end
of the BTZ protocol, when hypersensitivity was
maximal (panel d). PC1 was able to rapidly coun-
teract mechanical allodynia, and its effect was
maximal between 60 and 120 min and then pro-
gressively diminished, although a significant
difference from BTZ mice was still present 240
min after its administration.
a b
c d
Fig. 1 Anti-allodynic and anti-hyperalgesic effect of the PK-R antagonist PC1. a–c The effect of chronic PC1 on mechanical (a) and thermal (b)
allodynia and on thermal hyperalgesia (c) which develop in mice after bortezomib (BTZ) treatment (0.4 mg/kg 3 times week/4 weeks). PC1 was
administered (s.c. 150 μg/kg twice daily) for 14 days starting from day 14 (established hypersensitivity) until day 28. d The effect of a single PC1
injection (s.c. 150 μg/kg) performed at the end of BTZ protocol (day 28), when hypersensitivity was maximal. Paw withdrawal thresholds were
measured 30, 60, 120, 180, 210, and 240min after PC1 injection. Data represent mean ± SD of 6 mice/group. Statistical analysis was performed by
mean of two-way ANOVA followed by Bonferroni’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001 vs vehicle/CTR; °p < 0.05, °°°p < 0.001 vs BTZ;
+p < 0.05, +++p < 0.001 vs BTZ mice at day 14 (before starting PC1 treatment)
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PK and neuroimmune activation in peripheral and central
nervous system
The activation of PK system and the presence of neuro-
inflammation were evaluated in the main stations of
pain transmission (sciatic nerve, DRG, and spinal cord)
14 days after the first BTZ injection (corresponding to
BTZ cumulative dose of 2.4 mg/kg) and the end of
BTZ protocol (corresponding to BTZ cumulative dose
of 4.8 mg/kg).
Peripheral nervous system
PK system (PK2 and its receptors) in the sciatic
nerve Levels of PK2 were assessed by immunofluores-
cence staining. As reported in Fig. 2a, after 14 days of
BTZ treatment, we did not observe any change of PK2,
as demonstrated by the quantification of the percentage
of PK2 positive area (panel b). At the end of the chemo-
therapeutic schedule (day 28), PK2 levels were increased,
as shown by the representative immunofluorescence
images (panel a) and by the quantification of PK2 posi-
tive area (panel b; ***p < 0.001 vs CTR). The treatment
with PC1 can significantly reduce PK2 signal (panels a
and b; °°°p < 0.001 vs BTZ day 28). PK-R1 and PK-R2
expression levels were never affected by BTZ treatment
(panels c and d).
Effect of the PK-R antagonism on sciatic nerve
neuroinflammation As illustrated in Fig. 3, at day 14, be-
fore starting PC1, we measured an increase of CD68 both
as mRNA (panel a; ***p < 0.001 vs CTR) and as protein as
reported in the immunofluorescence images of panel c
and its quantification as percentage of CD68 positive area
(panel b; ***p < 0.001 vs CTR). Simultaneously (day 14),
we observed increased mRNA levels of TLR4 (panel
e; *p < 0.05 vs CTR) and of pro-inflammatory cyto-
kines IL-1β (panel g; **p < 0.01 vs CTR) and IL-6 (panel
h;*p < 0.05 vs CTR) without changes in TNF-α (panel f)
and in the anti-inflammatory cytokine IL-10 (panel i). By
increasing the cumulative dose of BTZ at day 28, levels of
CD68 (panels a, b, and c; **p < 0.01 vs CTR) and of TLR4
(panel e; *p < 0.05 vs CTR) were still upregulated. More-
over, at this time, we observed an increase in the levels of
all the evaluated pro-inflammatory cytokines: TNF-α,
IL-1β, IL-6 (panels f, g, and h respectively), and a decrease
of IL-10 expression (panel i;*p < 0.05 vs CTR). Immuno-
fluorescence double-staining images (panel d) illustrate
that PK2 immunoreactivity partially colocalizes with the
CD68 signal (panel d enlargement). PC1 treatment was
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Fig. 2 PK system activation in the sciatic nerve. a Representative images of PK2 immunofluorescence signal in the sciatic nerve sections of CTR,
BTZ 14 days (corresponding to c.d. 2.4 mg/kg), BTZ 28 days (corresponding to c.d. 4.8 mg/kg), and PC1 (BTZ + PC1) mice. Cell nuclei were
counterstained with DAPI (blue fluorescence). Quantitative analysis of PK2 signal (b) was computed as integrated optical density for arbitrary
areas (6 sections per animal, 5 animals per group). One-way ANOVA was used for statistical evaluation, followed by Bonferroni’s test for multiple
comparisons. ***p < 0.001 vs CTR; °°°p < 0.001 vs BTZ day 28. c, d mRNA levels of PK-R1 and PK-R2 respectively, measured by real-time qPCR, 14
days after the first BTZ administration (c.d. 2,4 mg/kg) and at the end of BTZ protocol (c.d. 4.8 mg/kg, day 28). Data represent mean ± SD of 6
mice/group. Statistical analysis was performed by mean of one-way ANOVA
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able to contrast macrophage recruitment and activation,
as demonstrated by the reduced levels of CD68 (panels a,
b, and c; °p < 0.05 vs BTZ day 28) and TLR4 levels (panel
e; °p < 0.05 vs BTZ day 28), to prevent the increase of the
TNF-α (panel f) and the decrease of IL-10 (panel i) and to
reduce the increased levels of IL-1β and IL-6 (panel g; °p
< 0.05 vs BTZ day 28 and panel h; °°°p < 0.001 vs BTZ
day 28). Consistent with what was already reported and
quantified in Fig. 2a and b, PK2-positive immunoreac-
tivity is lost in PC1-treated animals (panel d).
PK system in DRG As illustrated in Fig. 4, at day 14,
we did not observe any significant change in PK system
in DRG. PK2 immunoreactivity is reported in panel a
and quantified in panel b, while PK-R1 and PK-R2 are
reported as mRNA in panels c and d respectively. How-
ever, at the higher BTZ cumulative dose, we observed a
consistent increase of PK2 signal as shown by immuno-
fluorescence representative images (panel a) and by
the increase of percentage of PK2 positive area (panel
b;*** p < 0.001 vs CTR), as well as an upregulation of
a c
d
b
e
f g h i
Fig. 3 Effect of PC1 treatment on macrophage activation and cytokine levels in the sciatic nerve. a, b mRNA levels of CD68 and the percentage
of CD68 positive area in the sciatic nerve of CTR, BTZ 14 days (day 14 corresponding to c.d. 2,4 mg/kg), BTZ 28 days (day 28, corresponding to c.d.
4,8 mg/kg), and PC1 (BTZ + PC1) mice. Quantitative analysis of CD68 signal was computed as integrated optical density for arbitrary areas (6 sections
per animal, 5 animals per group). c Representative immunofluorescence images of CD68 in the sciatic nerve sections of the same experimental groups.
One-way ANOVA was used for statistical evaluation, followed by Bonferroni’s test for multiple comparisons. **p < 0.01, ***p < 0.001 vs CTR; °p < 0.05 vs
BTZ day 28. d Immunofluorescence double-staining shows the colocalization (yellow, arrowhead) of PK2 (green) with CD68 (activated macrophages,
red) in the sciatic nerve of CTR, BTZ day 14, BTZ day 28, and BTZ + PC1 mice (PC1). Cell nuclei were counterstained with DAPI (blue fluorescence). e–h
The mRNA levels of TLR4 and of the pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 respectively. i The mRNA of the anti-inflammatory cytokine
IL-10. All the measurements were performed 14 days after the first BTZ administration (c.d. 2.4 mg/kg), before starting PC1 treatment (CTR and BTZ
groups), and at the end of the BTZ protocol (c.d. 4.8 mg/kg) (CTR, BTZ, BTZ + PC1 groups). mRNA levels, determined by real-time qPCR,
were expressed in relation to GAPDH and presented as fold-increases over the levels of CTR animals (at the same time point). (a, e–i) Data represent
mean ± SD of 6 mice/group. At day 14, statistical analysis was performed by means of t test while at day 28 by using one-way ANOVA followed by
Bonferroni’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001 vs vehicle/CTR (at the same time point); °p < 0.05, °°°p < 0.001 vs BTZ day 28
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both PK-R1 and PK-R2 mRNA levels (panel c and d;
*** p < 0.001 vs CTR). PC1 treatment was able to contrast
the increase of both PK2 (panels a and b; °°°p < 0.001 vs
BTZ day 28) and PK-R1 (panel c; °°p < 0.01 vs BTZ day 28).
Effect of the PK-Rs antagonism on DRG
neuroinflammation BTZ promotes also in DRG, a rapid
macrophage recruitment and activation already evident
at day 14. At this time point, as shown in Fig. 5, we ob-
served in DRG sections increased levels of CD68 mRNA
(panel a; *p < 0.05 vs CTR) and CD68 protein as re-
ported by immunofluorescence pictures (panel c) and
the quantification of percentage of CD68 positive area
(panel b; ***p < 0.001 vs CTR). Simultaneously, we ob-
served an increase of TLR4 mRNA (panel e; *p < 0.05 vs
CTR) and a pro-inflammatory cytokine profile due to in-
creased mRNA levels of the pro-inflammatory cytokines
TNF-α (panel f; *p < 0.05 vs CTR) and IL-6 (panel h;
*p < 0.05 vs CTR) and a decrease of the
anti-inflammatory cytokine IL-10 (panel i; *p < 0.05 vs
CTR). This pattern is also evident at day 28 when also
IL-1β (panel g; **p < 0.01 vs CTR) is upregulated while
no significant changes were observed for IL-10 (panel i)
at this time. Immunofluorescence double-staining im-
ages illustrate that CD68 signal colocalizes in part with
PK2 signal (panel d enlargement). PC1 treatment was
able to normalize the levels of CD68 (panels a, b, and c;
°°° p < 0.001 vs BTZ day 28), of TLR4 (panel e; °°p <
0.001 vs BTZ day 28), and of all pro-inflammatory cyto-
kines investigated. As expected (see also Fig. 4), PK2 ac-
tivation was switched off in PC1-treated mice and the
association with CD68 was not present anymore.
Central nervous system
PK system in the spinal cord As described above for
the PNS, also in the spinal cord 14 days after the first
BTZ treatment, both PK2 (Fig. 6a, b) and PK-Rs receptor
(Fig. 6c, d) levels appear comparable to those of the con-
trol mice. At the end of the chemotherapeutic schedule
(day 28), BTZ increases PK2 signal in the dorsal horns of
the spinal cord, as shown in the immunofluorescence pic-
tures (panel a) and quantification of percentage of PK2
positive area (panel b; ***p < 0.001 vs CTR). An increase of
PK-R1 and PK-R2 receptors (panels c and d; ***p < 0.001
vs CTR) was also present at this time point. Therapeutic
treatment with PC1 was able to contrast PK system (PK2
and PK-R receptors) increase in the spinal cord (panels a,
b, c, and d; °°°p < 0.001 vs BTZ day 28).
Effect of PK antagonism on spinal cord
neuroinflammation As illustrated in Fig. 7, the spinal
cord was marginally affected by the lower cumulative BTZ
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Fig. 4 PK system activation in DRG. a Representative images of PK2 immunofluorescence signal in DRG sections of CTR, BTZ 14 days, BTZ 28 days,
and PC1 (BTZ + PC1) mice. Quantitative analysis of PK2 signal (b) was computed as integrated optical density for arbitrary areas (6 sections per
animal, 5 animals per group). One-way ANOVA was used for statistical evaluation, followed by Bonferroni’s test for multiple comparisons. *p < 0.05,
***p < 0.001 vs CTR; °°°p < 0.001 vs BTZ day 28. c, d mRNA levels of PK-R1 and PK-R2 respectively, measured by real-time qPCR, 14 days after the first
BTZ administration (c.d. 2.4 mg/kg) in CTR and BTZ mice and at the end of the BTZ protocol (c.d. 4,8 mg/kg) in CTR, BTZ, and BTZ + PC1. mRNA levels,
determined by real-time qPCR, were expressed in relation to GAPDH and presented as fold increases over the levels of CTR animals (at the same time
point). Data represent mean ± SD of 6 mice/group. At day 14, statistical analysis was performed by means of t test while at day 28 by one-way ANOVA
followed by Bonferroni’s post-test. ***p < 0.001 vs vehicle/CTR (at the same time point); °°p < 0.01 vs BTZ day 28
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dose: in fact, at day 14, we only observed an increase of
GFAP immunofluorescence signal: panel c reports a repre-
sentative image and panel b its quantification as percentage
of GFAP positive area (**p < 0.01 vs CTR). No other signifi-
cant change was present. Increasing the cumulative dose of
BTZ, at day 28, we observed an upregulation of CD68
(panel a; **p < 0.01 vs CTR) and TLR4 mRNA (panel d;
***p < 0.001 vs CTR). These alterations were concurrent to
increased levels of IL-1β (panel f; ***p < 0.001 vs CTR) and
decreased levels of the anti-inflammatory cytokine IL-10
(panel h; ***p < 0.001 vs CTR). No alterations in mRNA
levels of TNF-α (panel e) and IL-6 (panel g) were detected.
In this tissue, as shown in panel c, immunofluorescence
double-staining images illustrate that PK2 signal is
associated with GFAP. PC1 was able to counteract the im-
mune/glial activation in the lumbar spinal maintaining low
levels of CD68 and TLR4 (panels a, °°p < 0.01 vs BTZ
day 28, and d °°°p < 0.001 vs BTZ day 28), preserving a
correct pro-/anti-inflammatory cytokine balance
(panels f and h; °°°p < 0.001 vs BTZ day 28) and oppos-
ing to a dose-related GFAP increase (panel b and c).
However, confirming the decrease of PK2 signal after
PC1 treatment (Fig. 6), also PK2/GFAP colocalization
disappears in PC1-treated animals (Fig. 7c).
Morphological studies: electron microscopy
evaluations Ultrastructural examination of DRG was
performed to assess a protective role of the PK
a
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e
f g h i
c
d
Fig. 5 Effect of PC1 chronic treatment on macrophage activation and cytokine levels in DRG. a, b mRNA levels of CD68 and the percentage of
CD68 positive area in DRG of CTR, BTZ 14 days (corresponding to c.d. 2.4 mg/kg), BTZ 28 days (corresponding to c.d. 4.8 mg/kg), and PC1 (BTZ
+ PC1) mice. Quantitative analysis of CD68 signal was computed as integrated optical density for arbitrary areas (6 sections per animal, 5
animals per group). One-way ANOVA was used for statistical evaluation, followed by Bonferroni’s test for multiple comparisons. ***p < 0.001 vs
CTR; °°°p < 0.001 vs BTZ day 28. c Representative images of CD68 immunofluorescence signal in DRG sections while d immunofluorescence
double staining images shows the colocalization (white arrowhead) of PK2 (green) with CD68 (activated macrophages, red) in CTR, BTZ 14
days, BTZ 28 days, and PC1 (BTZ + PC1) mice. e–h the mRNA levels of TLR4 and of the pro-inflammatory cytokines TNF-α, IL-1β, and IL-6. i The
anti-inflammatory cytokine IL-10. All the measurements were performed 14 days after the first BTZ administration, before starting PC1
treatment (CTR and BTZ groups), and at the end BTZ/BTZ + PC1 protocol (CTR, BTZ, BTZ + PC1 groups). (a, e–i) Data represent mean ± SD of 6
mice/group. At day 14, statistical analysis was performed by means of t test while at day 28 by means of one-way ANOVA analysis of variance
followed by Bonferroni’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001 vs vehicle/CTR; °p < 0.05,°°p < 0.01, °°°p < 0.001 vs BTZ day 28
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antagonist on a progressive neuronal damage due to
BTZ cumulative dose.
Considering DRG, in physiological conditions, each
nerve cell body is usually enveloped by a satellite glial cell
sheaths. As illustrated in the electron microscopy images,
ultrastructural examination of the control ganglia (Fig. 8a)
confirmed the above described organization, and in all
cells of the DRG, there was no evidence of morphological
alterations. Animals subjected to BTZ administration
already at day 14 showed some ultrastructural alterations;
in particular, some satellite glial cell sheaths were partially
detached from their own enveloped nerve cell bodies.
Moreover, a greater number of neurons and satellite glial
cells exhibited swollen mitochondria intermingled with
some mitochondria of normal morphological feature
(panel b). Increasing the cumulative dose, 28 days after the
first BTZ administration, the ultrastructural examination
of DRG (Fig. 8c) showed that in many cases, the satellite
glial cell sheaths were detached from the nerve cell bodies.
Both the two cell types showed formation of clear vacuoli-
zation scattered within the cytoplasm. Some of these vac-
uoles were due to swollen mitochondria, while the largest
flattened and membrane-limited structures corresponded
to enlarged endoplasmic reticulum cisternae. Some
neurons had a rather dark nucleus instead of a normally
euchromatic one. After PC1 administration, most neurons
and satellite glial cells appeared well preserved, even if it is
evident that some nerve cell bodies and satellite glial cells
still showed some clear vacuoles scattered in the cyto-
plasm (Fig. 8d).
PK2 measurement in serum Figure 9 shows PK2 protein
levels measured in the serum at day 14 (before starting PC1
treatment) and at the end of the chemotherapeutic/PC1
treatment (day 28). In BTZ-treated mice, an increase of
serum PK2 levels was observable already 14 days after the
first BTZ injection (*p < 0.05 vs CTR). PK2 levels were still
high in BTZ mice at day 28 (**p < 0.01 vs CTR). PC1 treat-
ment was able to completely normalize altered serum PK2
levels (°°°p < 0.001 vs BTZ day 28).
Effect of PK antagonism on hypersensitivity during
repeated cycles of BTZ As shown in Fig. 10, after
the suspension of a first BTZ cycle of the duration
of 28 days, mice were monitored over time until
they completely recovered, returning to their basal
mechanical thresholds. At day 84, animals started
a new BTZ treatment with a schedule that was
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Fig. 6 PK system activation in the spinal cord. a Representative images of PK2 immunofluorescence signal in spinal cord sections of CTR, BTZ 14
days (corresponding to c.d. 2,4 mg/kg), BTZ 28 days (corresponding to c.d. 4.8 mg/kg), and PC1 (BTZ + PC1) mice. Quantitative analysis of PK2
signal (b) was computed as integrated optical density for arbitrary areas (6 sections per animal, 5 animals per group). One-way ANOVA was used
for statistical evaluation, followed by Bonferroni’s test for multiple comparisons. *p < 0.05, ***p < 0.001 vs CTR; °°°p < 0.001 BTZ day 28. c, d mRNA
levels of PK-R1 and PK-R2 respectively, measured by real-time qPCR, 14 days after the first BTZ administration (CTR and BTZ) mice and at the end
of the BTZ protocol (c.d. 4,8 mg/kg) in CTR, BTZ, and BTZ + PC1. mRNA levels, determined by real-time qPCR, were expressed in relation to
GAPDH and presented as fold increases over the levels of CTR animals (at the same time point). Data represent mean ± SD of 6 mice/group. At
day 14, statistical analysis was performed by means of t test while at day 28 by means of one-way ANOVA followed by Bonferroni’s post-test.
***p < 0.001 vs CTR; °°°p < 0.001 vs BTZ day 28
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identical to the one used for the first BTZ cycle. As
illustrated in the figure, a second BTZ cycle induces
in mice an allodynic effect similar to that observed in
the first BTZ cycle. However, in mice previously
treated with PC1 (first cycle), the allodynic effect in-
duced by BTZ was less intense in comparison with
that observed in BTZ-only re-treated mice (°p < 0.05
and °°°p < 0.001 vs BTZ at day 7 and 14 respectively).
In addition, a second PC1 chronic treatment (14 days
duration) was able to completely reverse allodynia (°°°
p < 0.001 vs BTZ day 28).
Discussion
In this paper, we describe for the first time the role
of prokineticin (PK) system in the development and
progression of bortezomib (BTZ)-induced peripheral
neuropathy (BIPN) that represents one of the main
dose-limiting side effects in BTZ therapy, and we demon-
strate a protective role of the PK antagonist PC1 on the
pathology progression. Prokineticins (PKs) belong to a
novel family of chemokines and are now recognized as im-
portant regulators at cross road of inflammation and pain
[13, 14]. PK2 can induce a pro-inflammatory macrophage
a
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Fig. 7 Effect of PC1 chronic treatment on neuroimmune activation in the lumbar spinal cord. a mRNA levels of CD68. b the percentage
of GFAP positive area in the spinal cord sections of CTR, BTZ 14 days (day 14 corresponding to c.d. 2.4 mg/kg), BTZ 28 days (day 28,
corresponding to c.d. 4.8 mg/kg), and BTZ + PC1 mice. Quantitative analysis of GFAP positive signal (b) was computed as integrated
optical density for arbitrary areas (6 sections per animal, 5 animals). Immunofluorescence double staining (c) shows the colocalization
(yellow) of PK2 (green) with GFAP (astrocytes, red) in the spinal cord of CTR, BTZ 14 days, BTZ 28 days, and PC1 (BTZ + PC1) mice. Cell
nuclei were counterstained with DAPI (blue fluorescence), statistical analysis was performed by means of one-way ANOVA analysis of
variance followed by Bonferroni’ s post-test. **p < 0.05, ***p < 0.01 vs CTR. d–g mRNA levels of TLR4 and of the pro-inflammatory
cytokines TNF-α, IL-1β, and IL-6 respectively while h reports the levels of the anti-inflammatory cytokine IL-10. All the measurements were
performed 14 days after the first BTZ administration, before starting the PC1 treatment (CTR and BTZ groups), and at the end of the
BTZ/BTZ + PC1 protocol (CTR, BTZ, BTZ + PC1 groups). mRNA levels, determined by real-time qPCR, were expressed in relation to GAPDH
and presented as fold increases over the levels of CTR animals (at the same time point). (a, d–h) Data represent mean ± SD of 6 mice/
group. At day 14, statistical analysis was performed by means of t test while at day 28 by means of one-way ANOVA followed by
Bonferroni’s post-test. ***p < 0.001 vs CTR; °°°p < 0.001 vs BTZ day 28
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phenotype [12] and nociceptive sensitization [27] and are
involved in the development of inflammatory and patho-
logical pain [15].
In our protocol, BIPN was induced in mice by using a
BTZ dosage able to induce a detectable neuropathic
phenotype limiting systemic side effects [22]. To assess
the role of PK system in BIPN development, we per-
formed biochemical and electron microscopy analysis at
two different time points: 14 days after the first BTZ in-
jection, before starting PC1 treatment, and at the end of
chemotherapeutic schedule (day 28). Therapeutic treat-
ment with the PK antagonist PC1 was started after veri-
fying in mice the presence of hypersensitivity.
Our behavioral evaluations showed that BTZ was able
to induce in mice a dose-related neuropathy character-
ized by the presence of allodynia and hyperalgesia. Pre-
clinical data have demonstrated that antineoplastic drugs
can activate both innate and adaptive immune responses
as well as peripheral and central neuronal accessory cells
like satellite cells, Schwann cells, astrocytes, and micro-
glia [4, 28]. In particular, chemotherapeutics can cross
the blood-nerve barrier, accumulating in dorsal root gan-
glia and in the peripheral nerves and exerting a toxic ac-
tion with consequent immune cell infiltration and
activation [8]. Consistently, our biochemical and im-
munofluorescence results indicate that after 14 days of
BTZ, in the presence of an hyperalgesic and allodynic
state, PNS stations are characterized by increased levels
of macrophage activation markers, i.e., CD68 and TLR4,
and by the presence of a pro-inflammatory cytokine pro-
file due to high levels of the investigated pro-inflamma-
tory cytokines (TNF-α, IL-1β, and IL-6) and low levels
of the anti-inflammatory cytokine IL-10 which is par-
ticularly evident in DRG. Moreover, our electron micros-
copy evaluations demonstrated that DRG of BTZ mice
are characterized by ultrastructural abnormalities like
Fig. 8 Morphological evaluation of DRG. As shown in a no morphological alterations are evident in both nerve cell bodies (N) and satellite glial
cell (sc) sheaths of CTR mice. nu, nerve cell body nucleus. After 14 days of bortezomib, neurons (N) and satellite glial cells (sc) exhibit swollen
mitochondria intermingled with some mitochondria of normal morphological features. nu, nerve cell body nucleus (b). At the end of BTZ
treatment (day 28), severe morphological abnormalities like swollen mitochondria and enlarged endoplasmic reticulum cisternae scattered within
the cytoplasm of both nerve cell bodies (N) and satellite glial cells (sc) can be seen (c). Some neurons show a rather dark nucleus (nu). Arrow
points to a satellite glial cell (sc) sheath partially detached from the nerve cell body (N). In bortezomib + PC1 group (d), neurons (N) and satellite
glial cells (sc) appear quite preserved, although some clear vacuoles scattered in the cytoplasm are still present. Bar = 5 μm (also applies to a–c)
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Fig. 9 PK2 serum levels. PK2 serum levels were measured by ELISA 14 days after the first BTZ administration, before starting the PC1 treatment
(CTR and BTZ groups), and at the end of the BTZ/BTZ + PC1 protocol (CTR, BTZ, BTZ + PC1 groups). Data represent mean ± SD of 6 mice/group.
At day 14, statistical analysis was performed by means of t test while at day 28 by means of one-way ANOVA followed by Bonferroni’s
post-test.*p < 0.05, **p < 0.01 vs CTR; °°°p < 0.001 vs BTZ day 28
Fig. 10 Effect of PK antagonism on mechanical allodynia during repeated cycles of BTZ. Following the interruption of a classical BTZ protocol of
28 days (BTZ 0.4 mg/kg 3 times week/4 weeks) and PC1 (s.c. 150 μg/kg twice day) chronic treatment (from BTZ day 14 to 28), mice progressively
recovered from BIPN. At day 84, in the presence of basal mechanical thresholds, mice that have been previously treated with the chemotherapeutic
drug (first BTZ cycle) underwent a second identical treatment with BTZ (BTZ 0.4mg/kg, 3 times week/4 weeks). At day 98, mice previously treated with
PC1 started a new chronic treatment with the antagonist. All animals were monitored until the end of the second BTZ and PC1 treatment (28 days
since the beginning of the second cycle corresponding to 112 days after the first BTZ injection). Data represent mean ± SD of 6 mice/group. Statistical
analysis was performed by mean of two-way ANOVA followed by Bonferroni’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001 vs vehicle/CTR;
°p < 0.05, °°p < 0.01, °°°p < 0.001 vs BTZ
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the presence of some partially detached satellite cell
sheaths and some swollen mitochondria in neurons and
satellite cells. At this time point, we only observed an in-
crease of GFAP in the spinal cord without measuring
any other biochemical alteration. Our results showing an
increase of CD68 marker and of TLR4 expression in the
peripheral nervous tissues are consistent with the recent
literature that suggests the importance of macrophage
infiltration and activation in PNS in CIPN development
[8]. For example, it has been recently demonstrated that
the intravenous immunoglobulin administration was
able to reduce or prevent BTZ-induced heat and mech-
anical allodynia in rat by decreasing or preventing M1
macrophage infiltration [10] in the peripheral nerves. In
our study, by increasing the BTZ cumulative dose (day
28), we observed a further lowering of the response
thresholds to mechanical and thermal stimuli in
BTZ-treated animals. The increased hypersensitivity cor-
relates with a more severe structural damage in DRG
and with the appearance of a more pronounced neuroin-
flammatory condition also evident at the spinal cord
level. Interestingly, after 28 days of BTZ treatment, we
also observe an overexpression of PK system in all the
tissues involved in pain transmission (sciatic nerve,
DRG, spinal cord). Immunofluorescence data suggest
that in PNS at the higher BTZ dose, CD68 + cells
co-express PK2. Therefore, we can suppose that infiltrat-
ing activated macrophages may represent an important
source of PK2 in DRG and sciatic nerve even if it ap-
pears evident that other cell types like satellite cells and
neurons may contribute to PK2 increase. In our para-
digm, the activation of the PK system in BIPN is delayed
in comparison with painful symptoms and the preco-
cious neuroinflammation. This later PK activation was
somehow surprising, since in previous work from ours
[13, 14] and other groups, PK system [20] activation well
correlated with the development of hypersensitivity.
Here, we demonstrated that in BIPN, this chemokine
family has however an important role in sustaining,
maintaining, and worsening hypersensitivity, neuroin-
flammation, and structural damage of DRG. In fact,
chronic treatment with PC1, even if it was started in the
presence of an established hypersensitivity, was able to
counteract the further decrease of mechanical and thermal
thresholds, to preserve against the neurotoxic damage to
DRG and to reverse the established neuroinflammation,
rebalancing pro- and anti-inflammatory cytokines in sci-
atic nerve and DRG. We can assume that during BTZ
treatment, infiltrated and resident-activated immune cells,
in association with satellite cells and Schwann cells, pro-
duce pro-inflammatory cytokines leading to a further re-
cruitment of immune cells into damaged nervous tissues.
These infiltrating macrophages not only produce PK2 but
also express PK-Rs receptors [26]; hence, PK2 can act in
autocrine or paracrine way sustaining a neuroinflamma-
tory loop that exacerbate the neuronal damage and sustain
a progressive glial activation at the spinal cord level [20].
A possible signaling pathway could be the one suggested
by the group of Qu et al. [28]. Authors demonstrated that
STAT3 signaling plays a crucial role in PK2 regulation and
that phosphorylated STAT3 can directly bind to the Pk2
promoter. Furthermore, a recent study [29] demonstrated
that phosphorylated STAT3 levels were significantly in-
creased after BTZ administration and that STAT3 activa-
tion in DRG contributes to BIPN. On the basis of these
data, we can speculate that the activation of STAT3, con-
sequent to pro-inflammatory cytokine increase in the per-
ipheral nervous stations [30], could be one of the
mechanisms involved in the PK2 upregulation. The effect
of PC1 may be in part related to its ability to reduce
macrophage activation and infiltration in PNS and to pre-
vent PK system upregulation that plays a crucial role in
prompting spinal cord neuroinflammation. In addition, as
also supported by the acute antiallodinic effect of PC1,
PKs can also act on PK-Rs expressed by neurons and glial
cells enhancing pain pathway transmission [17] which also
occurs through TRPV1 sensitization [31, 32]. Our results
also confirm the importance of astrocytes in CIPN [33]. In
fact, in our experiments, GFAP is the only marker that we
find precociously activated in the spinal cord. It was re-
cently suggested that the presence of mechanical hyper-
sensitivity due to BTZ treatment correlated to an
upregulation of GFAP [34, 35], and more recently, Salve-
mini’s group described that the development of BIPN is
lost when S1PR1 (sphingosine-1-phosphate receptor 1) is
deleted in astrocytes, suggesting a central role of astro-
cytes in sustaining CNS sensitization [33]. Interestingly, by
blocking the activation of the PK system with PC1, we
prevent a further neuroinflammatory condition in the
spinal cord. In BTZ + PC1-treated animals, in fact, we did
not detect any increase of glial activation markers CD68
and TLR4 that are indeed significantly enhanced in BIPN
animals after 28 days of BTZ treatment. As already ob-
served in other experimental models, IL-1 and IL-10 ap-
pear to be the main cytokines modulated in the spinal
cord in the presence of a neuropathic state and the
treatment with PC1 is able to prevent the IL-1/IL-10 un-
balance. We can therefore hypothesize that in the spinal
cord, there is an early activation of astrocytes that is inde-
pendent from the PK system. Astrocytes start to produce
PK2, as demonstrated by the colocalization of PK2 and
GFAP signals in the immunofluorescence experiments
and confirming what we already observed in the CCI
model [14]. PK2 promotes microglia activation and cyto-
kine alterations that may participate in central
sensitization; antagonizing the PK system prevents this
later activation. The precocious astrocyte activation is not
completely reverted by the PK antagonism and may be
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responsible for the only partial anti- hyperalgesic effect
observed in PC1 mice. We must however underline that
in PC1-treated mice, we did not observe a BTZ
dose-related increase of GFAP signal, suggesting that
blocking PK2 may be useful to control astrogliosis. More-
over, our data support the well-known flow of neuroim-
mune activation from the periphery to the central nervous
system [36–38] at the basis of the development of patho-
logical pain and underline the role of the prokineticin sys-
tem in this sensitization process.
In this study, we also measured circulating levels of
PK2. PK2 is a secreted protein, and elevated levels of the
chemokine have been reported in serum from mice with
experimental EAE autoimmune disease [39] as well as in
multiple sclerosis patients. In BTZ-treated mice, we also
found significant elevated levels of PK2 already after 14
days of BTZ treatment, therefore preceding the PK2 ac-
tivation in nervous tissues. We can speculate that per-
ipheral leukocytes may be the main source of the
chemokine, since monocytes, granulocytes, and lympho-
cytes produce and release PK2 when activated [11, 16,
40]. The cytotoxic action exerted by BTZ and the pres-
ence of a neuroinflammatory condition in PNS stations
could represent an activation signal for peripheral im-
mune cells. However, further experiments are needed in
order to understand the source of PK2 in blood from
BIPN animals.
Finally, the data reported in this study could have
translational implications. First of all, considering that
BIPN develops in about 1/3 of BTZ-treated patients,
PC1 may be administered only when the symptoms
have appeared allowing patients continue the chemo-
therapeutic treatment. In addition, we show that PC1
has a protective role in a two-cycle BTZ schedule: in
fact, in the second cycle, the allodynic effect promoted
by BTZ is less evident in mice previously treated with
PC1 if compared to that observed in BTZ-only
re-treated mice. Furthermore, the second PC1 treat-
ment completely normalizes the mechanical thresholds.
Considering that patients often undergo multiple che-
motherapeutic cycles, the protective role exerted by
PC1 on a second chemotherapeutic cycle could be clin-
ically relevant in order to slow down the re-appearance
of the side effects. We plan to deeply investigate the
reason behind this protective role of PC1 in future
studies. At the moment, we can only speculate that the
protective effect exerted by PC1 could be due to its
ability to counteract neuroinflammation and more
likely to its protective role on DRG ultrastructure. It
can be hypothesized that chronic PC1 treatment may
induce long-lasting modification in the PK system or
enhance protective mechanisms that may be important
in a second BTZ cycle, but further experiments are
needed to sustain this possibility.
Conclusions
In conclusion, this work indicates the PK system as a
strategical pharmacological target to counteract the pro-
gression of BTZ-induced peripheral neuropathy. Block-
ing PK2 activity reduces progressive BTZ toxicity in the
DRG, reducing neuroinflammation and structural dam-
age, and may prevent spinal cord sensitization. Consid-
ering that the development of CIPN seems to be
independent from the primary mechanism of action of
the antitumoral drug [32], it could be important to verify
if the PK antagonism could be efficacious also to con-
trast peripheral neuropathy which follows the treatment
with other chemotherapeutics.
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